A
Alfonso E. Bello
Researcher at Joint Institute for Nuclear Research
Publications - 30
Citations - 1905
Alfonso E. Bello is an academic researcher from Joint Institute for Nuclear Research. The author has contributed to research in topics: Celecoxib & Famotidine. The author has an hindex of 15, co-authored 30 publications receiving 1782 citations. Previous affiliations of Alfonso E. Bello include University of Illinois at Chicago & Rosalind Franklin University of Medicine and Science.
Papers
More filters
Journal ArticleDOI
Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
Andrew Whelton,John G. Fort,Joseph A. Puma,Diane Normandin,Alfonso E. Bello,Kenneth M. Verburg +5 more
TL;DR: In this article, the authors evaluated the cardiorenal safety of two new cyclooxygenase-2-specific inhibitors, celecoxib and rofecoxib, in a 6-week, randomized, parallel-group, double-blind trial.
Journal ArticleDOI
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
Gurkirpal Singh,John G. Fort,Jay L. Goldstein,Roger A. Levy,Patrick S. Hanrahan,Alfonso E. Bello,Lilia Andrade-Ortega,Carl B. Wallemark,Naurang M. Agrawal,Glenn M. Eisen,William F. Stenson,George Triadafilopoulos +11 more
TL;DR: In the treatment of osteoarthritis, celecoxib is as effective as the nonspecific NSAIDs naproxen and diclofenac, but has significantly fewer serious upper gastrointestinal events.
Journal ArticleDOI
Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis
TL;DR: In patients with controlled hypertension on a fixed antihypertensive regimen, careful monitoring of BP is warranted after the initiation of celecoxib or rofecoxib therapy.
Journal ArticleDOI
Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders:a review of the literature
Alfonso E. Bello,Steffen Oesser +1 more
TL;DR: A growing body of evidence provides a rationale for the use of collagen hydrolysate for patients with OA and suggests mechanisms that might help patients affected by joint disorders such as OA.
Journal ArticleDOI
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
TL;DR: Combined results of the REDUCE studies indicate that double-dose famotidine plus ib uprofen, given as a combination tablet, decreases endoscopic upper GI ulcers as compared with ibuprofen alone.